Objective: To present a review of the literature using evidence-based criteria for diagnosis and treatment of malignant growths in the ureteric remnant following nephrectomy for non-malignant disease. Methods: A database search using the key search words was performed, producing a total of 16 articles published between 1952 and 2009. The Oxford Centre for Evidence-Based Medicine classification was used. Statistical significance was tested by Pearson correlation. Demographic data, reason for nephrectomy, symptoms, time to diagnosis since initial nephrectomy, imaging modality and treatment option chosen, as well as histology and overall survival were reviewed. Results: Analysis was possible for 33 out of 63 cases reported in the literature. There was a male predominance (82%). Visible, painless haematuria was the presenting symptom in 72% of cases. Open ureterectomy was performed in the majority of patients (85%), while none had laparoscopic surgery. Transitional cell carcinoma was found in 66% of cases. Mean follow-up was 2.7 years. Metastases were detected in 36% and correlated significantly with cancer-specific mortality (95% CI: p < 0.001). Tumour stage, grade and cell type did not correlate significantly with mortality. Conclusion: Gross, painless haematuria is a feature highly suggestive of neoplastic change. Diagnosis often involves multimodality imaging and endoscopy. Complete ureterectomy with removal of bladder cuff, previously resected endoscopically, is the treatment of choice. Metastases at diagnosis and follow-up carry a worse prognosis.

Keywords:
Transitional cell carcinoma, Ureteral stump tumour, Recurrence, Haematuria, Simple nephrectomy
1.
Roupret M, Zigeuner R, Palou J, et al: European guidelines for the diagnosis and management of upper urinary tract urothelial cell carcinomas: 2011 update. Eur Urol 2011;59:584-594.
2.
Malek RS: Primary tumours of the ureteric stump. Br J Urol 1973;45:391-394.
3.
Babaian RJ, Johnson DE, Ayala AG, et al: Secondary tumors of ureter. Urology 1979;14:341-343.
4.
Collin P, Koenig P, Ouzzane A, et al: Environmental factors involved in carcinogenesis of urothelial cell carcinomas of the upper urinary tract. BJU Int 2009;104:1436-1440.
5.
Wisheart JD: Primary tumour of the ureteric stump following nephrectomy. Presentation of a case and a review of the literature. Br J Urol 1968;40:344-349.
6.
Loef JA, Casella PA: Squamous cell carcinoma occurring in the stump of a chronically infected ureter many years after nephrectomy. J Urol 1952;67:159-163.
7.
Phillips B, Ball C, Sackett D, et al: Oxford Centre for Evidence-Based Medicine Levels of Evidence, November 1998 (updated March 2009). http://www.cebm.net.
8.
Kim YJ, Jeon SH, Huh JS, et al: Long-term follow-up of ureteral stump tumors after nephrectomy for benign renal disease. Eur Urol 2004;46:748-752.
9.
Tolley DA, Castro JE: Primary urothelial tumor in ureteric stump. Urology 1978;11:398.
10.
Kageyama S, Sato S, Nakano M, et al: Primary tumor of the ureteral stump following nephrectomy for non-malignant disease. A case report. Nihon Hinyokika Gakkai Zasshi 1992;83:1330-1333.
11.
Ikeda I, Terao T, Masuda M, et al: Primary ureteral tumor in the residual ureter: a report of two cases. Hinyokika Kiyo 1992;38:707-710.
12.
El Khader K, Ouali M, Koutani A, et al: Transitional cell carcinoma on ureteral stump after nephrectomy for pyonephrosis. Prog Urol 2001;11:304-306.
13.
Inui M, Yamashita M, Taketa S, et al: Transitional cell carcinoma of the ureteral stump eight years after nephrectomy for benign disease. Int J Urol 2002;9:515-516.
14.
Sassa N, Matsuura O, Kamihira O, et al: Primary undifferentiated carcinoma of the ureteral stump; a case report. Nihon Hinyokika Gakkai Zasshi 2004;95:773-776.
15.
Okada Y, Yamamoto S, Akamatsu S, et al: Primary transitional carcinoma of the remaining ureter after nephrectomy for pyonephrosis: a case report. Hinyokika Kiyo 2005;51:101-103.
16.
Segawa N, Kotake Y, Noumi H, et al: Ureteral tumor occurring from remaining stump: a case report. Hinyokika Kiyo 2006;52:565-567.
17.
Park JY, Park J, Ku JH, et al: Transitional cell carcinoma in a remnant ureter after retroperitoneoscopic simple nephrectomy for benign renal disease. J Korean Med Sci 2009;24:992-994.
18.
Jaffe J, Friedman AC, Seidmon EJ, et al: Diagnosis of ureteral stump transitional cell carcinoma by CT and MR imaging. AJR Am J Roentgenol 1987;149:741-742.
19.
Pollack HM, Banner MP, Popky GL: Radiologic evaluation of the ureteral stump. Radiology 1982;144:225-230.
20.
Hirano D, Okada Y, Nagane Y, et al: Intravesical recurrence after surgical management of urothelial carcinoma of the upper urinary tract. Urol Int 2012;89:71-77.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.